Two years ago, Roche spent $1.9 billion to buy a startup, Flatiron Health, which uses data from patients’ electronic health records to better study cancer drugs. Now, many of the same investors are backing a new firm that will aim to do similar research in eye disease and neurology.
The twist: The new company, Verana Health, is obtaining its data by partnering with medical societies, including the American Academy of Ophthalmology, the largest organization of ophthalmologists, and the American Academy of Neurology.
About the Author Reprints
